Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

NCT00294658 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this trial is to determine if thymectomy combined with prednisone therapy is more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.

Conditions Studied

Interventions

  • PROCEDURE thymectomy plus prednisone
  • DRUG prednisone alone

Study Locations (20)

California

  • University of Southern California, Doheny Institute, 1450 San Pablo St — Los Angeles
  • University of California Irvine, 101 The City Drive S, Bldg. 22 C, Route 13 — Orange
  • California Pacific Medical Center, Castro St & Duboce Ave — San Francisco

Alabama

  • University of Alabama at Birmingham, Department of Neurology, Sparks Center, Suite 350, 1720 7th Avenue South — Birmingham
  • Data Coordination Center: University of Alabama at Birmingham — Birmingham

Florida

  • University of Florida Jacksonville, Tower I, 8th Floor, 580 W. 8th ST. — Jacksonville
  • University of Miami, 1120 NW 14th Street, Suite 1300 — Miami

Georgia

  • Emory University, 201 Dowman Dr — Atlanta
  • Augusta University, 1120 15th St — Augusta

Michigan

  • Wayne State University School of Medicine, 4201 St Antoine, 8D UHC — Detroit
  • William Beaumont Hospital, 3601 W. Thirteen Mile Road, Royal Oak — Royal Oak

Minnesota

  • University of Minnesota, Department of Neurology, MMC 295, 420 Delaware St. S.E., — Minneapolis
  • Mayo Clinic Rochester, 200 First St. SW — Rochester

Arizona

  • Barrow Neurological Institute, Saint Joseph's Hospital and Medical Center, 350 W Thomas Rd — Phoenix

Indiana

  • Indiana University, Dept of Neurology, Regenstrief Health Center, 6th floor, 1050 Walnut St, Indiana University Medical Center — Indianapolis

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2006-06
Est. Completion 2015-12
Phase Phase 3

Sponsor

University of Alabama at Birmingham

1,315 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00294658

The ClinicalTrials.gov registry entry for NCT00294658 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,315 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions — of which thymectomy plus prednisone is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00294658 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Alabama, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00294658 about?

NCT00294658 is a clinical study titled "Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy". The purpose of this trial is to determine if thymectomy combined with prednisone therapy is more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.

What is the current status of trial NCT00294658?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 126 participants. The study started on 2006-06. Estimated completion is 2015-12.

What conditions does trial NCT00294658 study?

This clinical trial studies the following conditions: Myasthenia Gravis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00294658?

The interventions under investigation include: thymectomy plus prednisone (PROCEDURE), prednisone alone (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00294658?

This trial is sponsored by University of Alabama at Birmingham, which has 1,315 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00294658 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial